Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Braegen-02
- Development stage
- Preclinical
- Lead developer
- Shanghai Braegen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Braegen-02 (also known as CF3CN or GLXC-24188) is a second-generation, orally bioavailable, brain-permeable small molecule agonist of the neurotrophic tyrosine kinase receptor type 2 (TrkB). Developed by Shanghai Braegen Pharmaceuticals, Braegen-02 is designed to activate the BDNF-TrkB signaling pathway, promoting neuronal survival and synaptic plasticity. In preclinical models, activation of TrkB by Braegen-02 triggers downstream Akt signaling, which phosphorylates and inhibits delta-secretase (asparaginyl endopeptidase), thereby reducing the cleavage of amyloid precursor protein (APP) and Tau. Braegen-02 is currently in preclinical development for the treatment of neurodegenerative disorders, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease.
- Other names
- 2410598-89-74-[6-oxo-2-(trifluoromethyl)-3H-pyrano[2,3-e]benzimidazol-8-yl]benzonitrileTrkB activator CF3CN
02
Targets
NTRK2 (Tropomyosin-related kinase receptor type B)
Beyond the preview
Go deeper on Braegen-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Braegen-02.